C-c(=x)-x-c Containing (x Is Chalcogen And At Least One X Is Other Than Oxygen) Patents (Class 514/513)
  • Patent number: 10316044
    Abstract: The present disclosure relates to certain chiral diaryl macrocyclic derivatives of the formula I pharmaceutical compositions containing them, and methods of using them to treat cancer, pain, neurological diseases, autoimmune diseases, and inflammation.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: June 11, 2019
    Assignee: TP Therapeutics, Inc.
    Inventors: Jingrong J. Cui, Yishan Li, Evan W. Rogers, Dayong Zhai, Wei Deng, Jane Ung
  • Patent number: 10308640
    Abstract: The present invention relates to compounds of formula I: for use in treating pulmonary arterial hypertension and associated conditions, where R1, R2 and R3 are the same or different and signify hydrogens, halogens, alkyl, alkylaryl, alkyloxy, hydroxy, nitro, amino, alkylcarbonylamino, alkylamino or dialkylamino group; R4 signifies hydrogen, alkyl, -alkylaryl or -alkylheteroaryl; X signifies CH2, oxygen atom or sulphur atom; n is 1, 2 or 3, with the proviso that when n is 1, X is not CH2; and the individual (R)- and (S)-enantiomers or mixtures of enantiomers and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: June 4, 2019
    Assignee: Bial-Portela & CA, S.A.
    Inventors: Patricio Manuel Vieira Araújo Soares Da Silva, Maria João Macedo Da Silva Bonifácio
  • Patent number: 9668478
    Abstract: The present invention provides a composition having an excellent controlling activity on a pest. The composition comprising a compound represented by Formula (1) and one or more pyrethroid compound(s) selected from Group (A) shows an excellent controlling activity on a pest.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: June 6, 2017
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: So Kiguchi, Soichi Tanaka
  • Patent number: 9561202
    Abstract: The present invention relates to compounds comprising the general formula (I), in which R1 and R2, which may be identical or different, are selected from the group comprising —H or a linear or branched alkyl group having from 1 to 6 carbon atoms or together form an aromatic or aliphatic ring with 5 or 6 atoms; Y and Z, which may be identical or different, are selected from the group comprising —H, —OH, —COOH, —OR3, —CH(OR3)COOH, in which R3 is selected from H, phenyl, benzyl, —CF3 or —CF2CF3, vinyl, allyl and a linear or branched alkyl group having from 1 to 6 carbon atoms.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: February 7, 2017
    Assignee: Nogra Pharma Limited
    Inventors: Giancarlo Naccari, Sergio Baroni
  • Patent number: 9273061
    Abstract: The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II, and methods for treating chronic pain in a disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.
    Type: Grant
    Filed: February 24, 2013
    Date of Patent: March 1, 2016
    Assignee: CELLIX BIO PRIVATE LIMITED
    Inventor: Mahesh Kandula
  • Patent number: 9173856
    Abstract: Disclosed herein are therapeutic regimens for treating or ameliorating a visual disorder associate with an endogenous retinoid deficiency in a subject by administering a therapeutically effective amount of a synthetic retinal derivative or a pharmaceutically acceptable composition comprising a synthetic retinal derivative according to the therapeutic regimen which leads to local recovery of visual functions such as visual fields, visual acuity and retinal sensitivity, among others.
    Type: Grant
    Filed: April 19, 2011
    Date of Patent: November 3, 2015
    Assignee: QLT INC.
    Inventors: H. Andrew Strong, Suzanne Cadden
  • Publication number: 20150133544
    Abstract: A novel substituted N-acetyl-L-cysteine (NAC) derivative and methods of using this compound for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.
    Type: Application
    Filed: November 7, 2014
    Publication date: May 14, 2015
    Inventors: Michael Neary, James Nieman, Steven Tanis, Daniel Lawton
  • Publication number: 20150133470
    Abstract: Novel substituted N-acetyl-L-cysteine (NAC) derivatives and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.
    Type: Application
    Filed: November 7, 2014
    Publication date: May 14, 2015
    Inventors: Michael Neary, James Nieman, Steven Tanis, Daniel Lawton, Garry Smith
  • Publication number: 20150031715
    Abstract: The invention relates to compounds of formula I: wherein R1, R2, and n are defined in the detailed description and claims. In particular, the present invention relates to the compounds of formula I for use in the manufacture and delivery of conjugated moieties such as small molecules, peptides, nucleic acids, fluorescent moieties, and polymers which are linked to VLA-4 integrin antagonists to target cells expressing VLA-4.
    Type: Application
    Filed: January 24, 2013
    Publication date: January 29, 2015
    Inventors: Robert Alan Goodnow, JR., Matthew Michael Hamilton, Achyutharao Sidduri
  • Publication number: 20140364493
    Abstract: The present invention aims at provision of a method for inhibiting remnant lipoprotein production and a remnant lipoprotein production inhibitor, which includes administering a compound having a CETP inhibitory activity to an administration subject. The remnant lipoprotein production inhibitor of the present invention contains a compound having a CETP inhibitory activity as an active ingredient.
    Type: Application
    Filed: January 15, 2014
    Publication date: December 11, 2014
    Applicant: Japan Tobacco Inc.
    Inventors: Hiroshi Okamoto, Noboru Furukawa, Tomohiko Sasase
  • Publication number: 20140336254
    Abstract: A family of covalent kinetic stabilizer compounds that selectively and covalently react with the prominent plasma protein transthyretin in preference to more than 4000 other human plasma proteins is disclosed. A contemplated compound corresponds in structure to Formula I, below, where the various substituents are defined within, and reacts chemoselectively with one or two of four Lys-15 ?-amino groups within the transthyretin tetramer. The crystal structure confirms the binding orientation of the compound substructure and the conjugating amide bond. A covalent transthyretin kinetic stabilizer exhibits superior amyloid inhibition potency, compared to a non-covalent counterpart, and inhibits cytotoxicity associated with amyloidogenesis.
    Type: Application
    Filed: April 14, 2014
    Publication date: November 13, 2014
    Inventors: Jeffery W. Kelly, Sungwook Choi
  • Patent number: 8871805
    Abstract: The disclosure herein provides the compounds of Formulas 1 and its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, transdermal administration, and/or injection. Such compositions may be used for the treatment of metabolic conditions, cystinosis, non-alcoholic Steatohepatitis, hypertriglyceridemia, and/or neurodegenerative disorders, and/or their associated complications.
    Type: Grant
    Filed: April 6, 2013
    Date of Patent: October 28, 2014
    Assignee: Krisani Biosciences Pvt. Ltd.
    Inventor: Mahesh Kandula
  • Patent number: 8853281
    Abstract: Compounds of the formula I wherein R1a is H; and R1b is C1-C6 alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are H, halo, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy; or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl; R3 is a branched C5-C10alkyl chain, C2-C4haloalkyl or C3-C7cycloalkylmethyl, R4 is Het, Carbocyclyl, optionally substituted as defined in the specification and pharmaceutically acceptable salts, hydrates and N-oxides thereof; are inhibitors of cathepsin S and have utility in the treatment of psoriasis, autoimmune disorders and other disorders such as asthma, arteriosclerosis, COPD and chronic pain.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: October 7, 2014
    Assignee: Medivir UK Ltd
    Inventors: Susana Ayesa, Anna Karin Belfrage, Bjorn Classon, Urszula Grabowska, Ellen Hewitt, Vladimir Ivanov, Daniel Jönsson, Pia Kahnberg, Peter Lind, Magnus Nilsson, Lourdes Odén, Mikael Pelcman, Horst Wähling
  • Publication number: 20140275246
    Abstract: A lipid composition comprising racecadotril, at least one surfactant and a lipid.
    Type: Application
    Filed: December 23, 2013
    Publication date: September 18, 2014
    Applicant: McNeil-PPC, Inc.
    Inventor: Der-Yang Lee
  • Publication number: 20140221476
    Abstract: The disclosure herein provides the compounds of Formulas 1 and its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, transdermal administration, and/or injection. Such compositions may be used for the treatment of metabolic conditions, cystinosis, non-alcoholic Steatohepatitis, hypertriglyceridemia, and/or neurodegenerative disorders, and/or their associated complications.
    Type: Application
    Filed: April 4, 2014
    Publication date: August 7, 2014
    Inventor: Mahesh Kandula
  • Patent number: 8779187
    Abstract: The present invention discloses a soft gelatin capsule formulation of a 15-keto-prostaglandin compound, which comprises: a soft gelatin capsule shell comprising gelatin and sugar alcohol as a plasticizer, and a mixture comprising a 15-keto-prostaglandin compound and a pharmaceutically acceptable vehicle which is filled in the shell. By encapsulating the 15-keto-prostaglandin compound in the specified soft gelatin capsule shell, stability of the compound is significantly improved.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: July 15, 2014
    Assignees: Sumcampo AG, R-Tech Ueno, Ltd.
    Inventors: Yukiko Hashitera, Ryu Hirata, Yasuhiro Harada, Ryuji Ueno
  • Patent number: 8772335
    Abstract: The present invention relates to adamantyl derivatives and their anti-cancer activity. Compounds of formulae I and II are provided as well as related methods of treatment and methods of synthesis.
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: July 8, 2014
    Assignee: Woman & Infants' Hospital of Rhode Island
    Inventors: Richard G. Moore, Rakesh K. Singh
  • Publication number: 20140171502
    Abstract: The present invention relates to a process for the preparation of S-[2-[1-(2-ethylbutyl)cyclohexylcarbonylamino]-phenyl] 2-methylthiopropionate which is useful as a pharmaceutically active compound.
    Type: Application
    Filed: December 18, 2013
    Publication date: June 19, 2014
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Hans-Juergen Mair, Reinhard Reents, Michelangelo Scalone, Shaoning Wang, Andreas Zogg
  • Patent number: 8754127
    Abstract: Disclosed herein are compounds that may be specific to PPAR and/or EGF receptors, and methods of making and using same.
    Type: Grant
    Filed: February 16, 2010
    Date of Patent: June 17, 2014
    Assignee: Nogra Pharma Limited
    Inventors: Sergio Baroni, Salvatore Bellinvia, Francesca Viti
  • Publication number: 20140155442
    Abstract: The present invention provides an agent for preventing the increase in a body weight (or for decreasing a body weight) or an anti-obesity agent each comprising at least one component selected from the group consisting of EPA and pharmaceutically acceptable salts, esters and derivatives thereof as an active ingredient for obesity in which the increase in the formation of hepatic lipid or the occurrence of fatty liver is mild, preferably the increase in the formation of hepatic lipid or the occurrence of fatty liver is not observed.
    Type: Application
    Filed: July 6, 2012
    Publication date: June 5, 2014
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Takayuki Ishida, Hiroyuki Kawano
  • Patent number: 8716337
    Abstract: A pharmaceutical composition comprising a drug substance consisting essentially of a pharmaceutically acceptable organic acid addition salt of an amine containing pharmaceutically active compound wherein the amine containing pharmaceutical active compound is selected from the group consisting of racemic or single isomer ritalinic acid or phenethylamine derivatives and the drug substance has a physical form selected from amorphous and polymorphic.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: May 6, 2014
    Assignee: Pisgah Laboratories, Inc.
    Inventors: Clifford Riley King, Stephen G. D'Ambrosio, David W. Bristol
  • Patent number: 8703815
    Abstract: A family of covalent kinetic stabilizer compounds that selectively and covalently react with the prominent plasma protein transthyretin in preference to more than 4000 other human plasma proteins is disclosed. A contemplated compound corresponds in structure to Formula I, below, where the various substituents are defined within, and reacts chemoselectively with one or two of four Lys-15 ?-amino groups within the transthyretin tetramer. The crystal structure confirms the binding orientation of the compound substructure and the conjugating amide bond. A covalent transthyretin kinetic stabilizer exhibits superior amyloid inhibition potency, compared to a non-covalent counterpart, and inhibits cytotoxicity associated with amyloidogenesis.
    Type: Grant
    Filed: October 14, 2010
    Date of Patent: April 22, 2014
    Assignee: The Scripps Research Institute
    Inventors: Jeffery W. Kelly, Sungwook Choi
  • Publication number: 20140045765
    Abstract: A method for inhibiting the autophagy of motor neurons in a subject is provided. The method comprises administrating to the subject an effective amount of an active ingredient selected from the group consisting of a compound of formula (I), a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable ester of the compound and combinations thereof: wherein A is a C1-C5 alkyl optionally having one or more unsaturated bonds and optionally being substituted by one or more substituents selected from a group consisting of —OH, ?O and C1-C3 alkyl; X is H, —OH, Y is O or S and can optionally combine with A to form a five-membered ring; and R1 is H or a substituted or unsubstituted C1-C20 alkyl, wherein one or more —CH2— of the C1-C20 alkyl are optionally being replaced by —NH— or —O—.
    Type: Application
    Filed: December 4, 2012
    Publication date: February 13, 2014
    Applicant: China Medical University
    Inventors: Shinn-Zong Lin, Horng-Jyh Harn, Tzyy-Wen Chiou, Kuo-Wei Hsueh
  • Publication number: 20140005262
    Abstract: A lipid composition comprising racecadotril, at least one surfactant and a lipid.
    Type: Application
    Filed: June 28, 2013
    Publication date: January 2, 2014
    Applicant: McNeil-PPC, Inc.
    Inventor: Der-Yang Lee
  • Publication number: 20140005261
    Abstract: A liquid composition comprising racecadotril and cyclodextrin.
    Type: Application
    Filed: June 28, 2013
    Publication date: January 2, 2014
    Applicant: McNeil-PPC, Inc.
    Inventors: Der-Yang Lee, Tusharmouli Mukherjee
  • Publication number: 20130338165
    Abstract: Methods of treating Parkinson's Disease comprising administering compounds that up-regulate cystine-glutamate exchange (system Xc?) and/or increase glutathione levels in the brain cells. Preferred compounds are cysteine/cystine prodrugs or N-acetyl cysteine (NAC) prodrugs.
    Type: Application
    Filed: June 17, 2013
    Publication date: December 19, 2013
    Inventors: David A. Baker, Daniel G. Lawton, Chad Beyer, Michael Neary
  • Patent number: 8592438
    Abstract: A plant disease control composition comprising, as an active ingredient, a compound of formula (I) or a salt thereof, and one or more anilinopyrimidine compounds selected from the group consisting of 4,6-dimethyl-N-phenyl-2-pyrimidinamine, 4-methyl-N-phenyl-6-(1-propynyl)-2-pyrimidinamine and 4-cyclopropyl-6-methyl-N-phenyl-2-pyrimidinamine has an excellent plant disease control effect.
    Type: Grant
    Filed: March 16, 2009
    Date of Patent: November 26, 2013
    Assignee: Sumitomo Chemical Intellectual Property Service, Ltd
    Inventors: Masanao Takaishi, Norio Kimura
  • Patent number: 8575217
    Abstract: The present invention is directed to methods for treating metabolic disorders with compounds that are conjugates. The conjugates of the present invention are comprised of salicylic acid, triflusal, diflusinal, salsalate, IMD-0354, ibuprofen, diclofenac, licofelone, or HTB, and one or more antioxidants.
    Type: Grant
    Filed: March 16, 2010
    Date of Patent: November 5, 2013
    Assignee: Genmedica Therapeutics SL
    Inventors: Alec Mian, Luc Marti Clauzel, Eric Mayoux, Silvia Garcia-Vicente, Marta Serrano Munoz, Antonio Zorzano Olarte, Julio Cesar Castro Palomino Laria
  • Publication number: 20130281520
    Abstract: The present invention is directed to methods for treating metabolic disorders with compounds that are conjugates. The conjugates of the present invention are comprised of salicylic acid, triflusal, diflusinal, salsalate, IMD-0354, ibuprofen, diclofenac, licofelone, or HTB, and one or more antioxidants.
    Type: Application
    Filed: March 14, 2013
    Publication date: October 24, 2013
    Inventors: Alec Mian, Luc Marti Clauzel, Eric Mayoux, Silvia Garcia Vicente, Marta Serrano Munoz, Antonio Zorzano Olarte, Julio Cesar Castro Palomino Laria
  • Publication number: 20130225680
    Abstract: The disclosure herein provides the compounds of Formulas 1 and its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, transdermal administration, and/or injection. Such compositions may be used for the treatment of metabolic conditions, cystinosis, non-alcoholic Steatohepatitis, hypertriglyceridemia, and/or neurodegenerative disorders, and/or their associated complications.
    Type: Application
    Filed: April 6, 2013
    Publication date: August 29, 2013
    Inventor: Mahesh Kandula
  • Publication number: 20130197059
    Abstract: The invention relates to compounds of formula I: wherein R1, R2, and n are defined in the detailed description and claims. In particular, the present invention relates to the compounds of formula I for use in the manufacture and delivery of conjugated moieties such as small molecules, peptides, nucleic acids, fluorescent moieties, and polymers which are linked to LFA-1 integrin antagonists to target cells expressing LFA-1.
    Type: Application
    Filed: January 24, 2013
    Publication date: August 1, 2013
    Applicant: Hoffmann-La Roche Inc.
    Inventor: Hoffmann-La Roche Inc.
  • Publication number: 20130143962
    Abstract: The present invention relates to adamantyl derivatives and their anti-cancer activity. Compounds of formulae I and II are provided as well as related methods of treatment and methods of synthesis.
    Type: Application
    Filed: December 6, 2012
    Publication date: June 6, 2013
    Applicant: WOMEN & INFANTS' HOSPITAL OF RHODE ISLAND
    Inventor: Women & Infants' Hospital of Rhode Island
  • Patent number: 8344024
    Abstract: An anhydrous color cosmetic composition comprising at least one resveratrol derivative and particulates; and an anhydrous emulsion skin care composition.
    Type: Grant
    Filed: May 27, 2008
    Date of Patent: January 1, 2013
    Assignee: ELC Management LLC
    Inventors: Anna Czarnota, Lisa Qu, Fatemeh Mohammadi, Julius R. Zecchino
  • Patent number: 8338639
    Abstract: The present invention provides a soft gelatin capsule formulation of a 15-keto-prostaglandin compound, which includes: a soft gelatin capsule shell including gelatin and sugar alcohol as a plasticizer, and a mixture including a 15-keto-prostaglandin compound and a pharmaceutically acceptable vehicle which is filled in the shell. By encapsulating the 15-keto-prostaglandin compound in the specified soft gelatin capsule shell, stability of the compound is significantly improved.
    Type: Grant
    Filed: August 16, 2011
    Date of Patent: December 25, 2012
    Assignees: Sucampo AG, R-Tech Ueno, Ltd.
    Inventors: Yukiko Hashitera, Ryu Hirata, Yasuhiro Harada, Ryuji Ueno
  • Publication number: 20120301439
    Abstract: Methods of treatment of diseases that include or are characterized by inappropriate or pathological neovascularization are disclosed. These diseases include diseases of the eye, such as diabetic retinopathy, retinopathy of prematurity, and choroidal neovascularization which can occur in age-related macular degeneration (AMD). Disclosed methods include administering agents that cause directly or indirectly upregulation of the ABCA1 transporter protein in macrophages. These agents include, without limitation, LXR agonists. In some embodiments, inhibitors of CETP expression or activity can also be effective. Administration routes can include, without limitation, intraocular, periocular, or systemic administration.
    Type: Application
    Filed: May 24, 2012
    Publication date: November 29, 2012
    Applicant: WASHINGTON UNIVERSITY
    Inventor: Rajendra S. Apte
  • Publication number: 20120270938
    Abstract: A family of covalent kinetic stabilizer compounds that selectively and covalently react with the prominent plasma protein transthyretin in preference to more than 4000 other human plasma proteins is disclosed. A contemplated compound corresponds in structure to Formula I, below, where the various substituents are defined within, and reacts chemoselectively with one or two of four Lys-15 ?-amino groups within the transthyretin tetramer. The crystal structure confirms the binding orientation of the compound substructure and the conjugating amide bond. A covalent transthyretin kinetic stabilizer exhibits superior amyloid inhibition potency, compared to a non-covalent counterpart, and inhibits cytotoxicity associated with amyloidogenesis.
    Type: Application
    Filed: October 14, 2010
    Publication date: October 25, 2012
    Inventors: Jeffery W. Kelly, Sungwook Choi
  • Publication number: 20120234721
    Abstract: The present invention provides compounds that are effective in treating central nervous system disorders and maintaining normal brain function. Methods of making and using the compounds are also provided.
    Type: Application
    Filed: September 9, 2011
    Publication date: September 20, 2012
    Applicant: Neurotherapeutics Pharma, Inc.
    Inventors: Daryl W. HOCHMAN, John J. Partridge
  • Publication number: 20120220596
    Abstract: The present invention provides cysteine and cystine prodrugs for the treatment of schizophrenia and drug addiction. The invention further encompasses pharmaceutical compositions containing prodrugs and methods of using the prodrugs and compositions for treatment of schizophrenia and drug addiction.
    Type: Application
    Filed: May 7, 2012
    Publication date: August 30, 2012
    Applicants: UWM RESEARCH FOUNDATION, INC., MARQUETTE UNIVERSITY
    Inventors: James M. Cook, David A. Baker, Wenyuan Yin, Edward Merle Johnson, II
  • Publication number: 20120213827
    Abstract: A process for controlling the crystallization of certain hydrophobic active pharmaceutical ingredients (APIs) from a supercooled liquid state by hot-melt extrusion processing is described. Also described is a pharmaceutical composition comprising a solid crystalline dispersion of a cholesterol ester transfer protein inhibitor in a hydrophilic excipient matrix. In the process of the present invention, the API is fed to an extrusion system in a crystalline state contemporaneously with carrier excipients where it is first converted to a non-crystalline state by the application of heat and then subsequently recrystallized in-situ by the removal of heat and application of shear. Recrystallization of the API is controlled by carrier formulation design and the hot-melt extrusion process parameters; i.e. barrel temperature profile, feed rate, etc.
    Type: Application
    Filed: February 17, 2012
    Publication date: August 23, 2012
    Inventors: Ashish Chatterji, Dipen Desai, Dave Alan Miller, Harpreet K. Sandhu, Navnit H. Shah
  • Patent number: 8232265
    Abstract: Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.
    Type: Grant
    Filed: October 10, 2006
    Date of Patent: July 31, 2012
    Assignee: Board of Trustees of the University of Alabama
    Inventors: Robin D. Rogers, Daniel T. Daly, Richard P. Swatloski, Whitney L. Hough, James Hilliard Davis, Jr., Marcin Smiglak, Juliusz Pernak, Scott K. Spear
  • Publication number: 20120157504
    Abstract: The present invention relates to a process for the preparation of S-[2-[1-(2-ethylbutyl)cyclohexylcarbonylamino]-phenyl]2-methylthiopropionate which is useful as a pharmaceutically active compound.
    Type: Application
    Filed: December 13, 2011
    Publication date: June 21, 2012
    Inventors: Hans-Juergen Mair, Reinhard Reents, Michelangelo Scalone, Shaoning Wang, Andreas Zogg
  • Publication number: 20120148662
    Abstract: The present invention relates to a novel stable S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate liposomal composition, a process for the preparation thereof and its use in the treatment of diseases.
    Type: Application
    Filed: December 6, 2011
    Publication date: June 14, 2012
    Inventors: Guenter Gross, Joseph Tardio
  • Publication number: 20120122844
    Abstract: The present invention provides the use of a neutral endopeptidase inhibitor, in the manufacture of a medicament for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The invention also relates to the use of a compound of Formula I: wherein R1, R2, R3, R5, X, A3, B1, s and n are defined herein, for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of contrast-induced nephropathy.
    Type: Application
    Filed: November 11, 2011
    Publication date: May 17, 2012
    Applicant: NOVARTIS AG
    Inventor: Shi Yin FOO
  • Publication number: 20120115946
    Abstract: The present invention relates to a hygroscopic matrix based formulation, a process for the preparation thereof and its use in the treatment of diseases.
    Type: Application
    Filed: November 3, 2011
    Publication date: May 10, 2012
    Inventors: Michaela Krabichler, Bernard Meyer, Carsten Winzenburg
  • Patent number: 8163797
    Abstract: The present invention provides oral pravastatin formulations comprising a physical mixture of pravastatin and at least one pharmaceutically-acceptable excipient, wherein the composition for at least 6 months after its preparation is stable and has a pH of greater than about 7 to less than 9, as well as methods for the preparation and use of these stable formulations.
    Type: Grant
    Filed: May 7, 2004
    Date of Patent: April 24, 2012
    Assignee: Actavis Elizabeth LLC
    Inventor: Alfred Liang
  • Patent number: 8138158
    Abstract: Compositions and methods for therapy of cystic fibrosis, asthma, and other conditions characterized by defective chloride transport are provided. The compositions comprise one or more compounds such as flavones and/or isoflavones, ascorbate and/or derivatives thereof capable of stimulating chloride transport in epithelial tissues. Therapeutic methods involve the administration (e.g., orally or via inhalation) of such compositions to a patient afflicted with cystic fibrosis, asthma, and/or another condition responsive to stimulation of chloride transport.
    Type: Grant
    Filed: March 11, 2010
    Date of Patent: March 20, 2012
    Assignee: Children's Hospital & Research Center at Oakland
    Inventors: Horst Fischer, Beate Illek
  • Patent number: 8084496
    Abstract: Resveratrol ferulate compounds and compositions.
    Type: Grant
    Filed: May 6, 2010
    Date of Patent: December 27, 2011
    Assignee: ELC Management LLC
    Inventors: Daniel H. Maes, Fatemeh Mohammadi, Lisa Qu, Anna Czarnota, Thomas Mammone, Lieve Declercq, Julius R. Zecchino
  • Patent number: 8080583
    Abstract: An emulsion cosmetic composition comprising at least one resveratrol derivative, a water phase, and an oil phase containing at least one linear or branched volatile or near volatile silicone and a method for delivering active resveratrol to the skin.
    Type: Grant
    Filed: May 27, 2008
    Date of Patent: December 20, 2011
    Assignee: ELC Management LLC
    Inventors: Daniel H. Maes, Fatemeh Mohammadi, Lisa Qu, Anna Czarnota, Thomas Mammone, Lieve Declercq, Julius R. Zecchino
  • Patent number: 8076372
    Abstract: Certain thiol and acylthiol compounds inhibit retrovirus growth by attacking the highly conserved zinc finger regions of essential viral proteins. These compounds, compositions containing them, and methods of using them to treat retroviral infections such as HIV are described. These compounds are also useful for preparation of vaccines comprised of inactivated retroviruses such as HIV, prevention of the transmission of such retroviruses, and detection of retroviral proteins.
    Type: Grant
    Filed: March 30, 2009
    Date of Patent: December 13, 2011
    Assignee: Government of the United States
    Inventors: John K. Inman, Atul Goel, Ettore Appella, Jim A. Turpin, Marco Schito
  • Publication number: 20110288168
    Abstract: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a hydroxamic acid group or a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, genetic disorders, e.g. Huntington's disease and spinal muscular atrophy and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy.
    Type: Application
    Filed: November 29, 2010
    Publication date: November 24, 2011
    Inventors: Hsuan-Yin Lan-Hargest, Robert J. Kaufman, Norbert L. Wiech